Matches in Nanopublications for { ?s ?p "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP930315.RAAUwm_RBtlZeEsN2fGovqAr2ZU9AX1u_N0rlE18hNslU130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP930315.RAAUwm_RBtlZeEsN2fGovqAr2ZU9AX1u_N0rlE18hNslU130_provenance.
- NP525686.RAzyn3e7gOFcXLFgpqqB8kNy325kEH8_dO0KOMMfk0rZc130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525686.RAzyn3e7gOFcXLFgpqqB8kNy325kEH8_dO0KOMMfk0rZc130_provenance.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_provenance.
- NP492016.RAc2DQbAp62veF2x5DN-tS_nMSPxuGzDM_HY6Zu1Rr6mw130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492016.RAc2DQbAp62veF2x5DN-tS_nMSPxuGzDM_HY6Zu1Rr6mw130_provenance.
- NP492940.RAXYZEbWIjOC8QOyeondmPTzF8C81Mr_ysw7JSLPAHL1A130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492940.RAXYZEbWIjOC8QOyeondmPTzF8C81Mr_ysw7JSLPAHL1A130_provenance.
- NP958422.RA5fMyllThk4pDZvAN-1ZKeIL9YdmBfA1PQEQGCymB3H0130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP958422.RA5fMyllThk4pDZvAN-1ZKeIL9YdmBfA1PQEQGCymB3H0130_provenance.
- assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP958423.RAbfF9NRQ3K2Kqm-HfRF8mw-i4TGCNoOHFjqEF2Wyexl0130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP958423.RAbfF9NRQ3K2Kqm-HfRF8mw-i4TGCNoOHFjqEF2Wyexl0130_provenance.
- NP958424.RAlMm95vQ_j5Oy6Pha7c2Rx4HtmeUdjJKAcYq6_evz5xs130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP958424.RAlMm95vQ_j5Oy6Pha7c2Rx4HtmeUdjJKAcYq6_evz5xs130_provenance.